Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14699614 | 1.00 | MAPT (0.50) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL26771623 | 0.89 | MAPT (0.50) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL15398648 | 0.87 | STS (0.64) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17991992 | 0.87 | LMNA (0.49) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17991980 | 0.85 | MAPT (0.48) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17992003 | 0.84 | MAPT (0.44) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17992004 | 0.84 | LMNA (0.54) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17991985 | 0.83 | LMNA (0.45) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17991993 | 0.83 | LMNA (0.45) | MAPTRAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL17991987 | 0.83 | MAPT (0.43) | MAPTRAB9ANPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355644-A1 | ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 | CREATIVE THERAPEUTICS GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-9409859-B2 | Substituted diphenyl derivatives | CREATIVE THERAPEUTICS GMBH (DE) | 2016-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355644-A1 | ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 | ACE, ACE2, SARS1 | MAPT 847/4885RAB9A 2059/4885NPC1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.